Inozyme Pharma is a global leader in developing therapies for rare mineralization disorders.
With our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. Two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and defects in these genes lead to abnormal mineralization.
We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.
With a well-defined regulatory strategy, robust financial backing, and a strong business acumen, we are just getting started.
Experience counts. With decades of clinical, scientific, regulatory, commercial, and financial experience backing our work, we push boundaries to provide hope and transform patient lives.
Demetrios Braddock is an Associate Professor at Yale University, where he practices hematopathology and leads a laboratory investigating questions at the intersection of disease pathogenesis and biophysical chemistry. Dr. Braddock has made important contributions to the understanding of the histopathology of disorders of aberrant calcification.
As the scientific founder of Inozyme Pharma and a member of the Scientific Advisory Board, Dr. Braddock continues to collaborate with the company. Dr. Braddock earned his M.D. from the University of Chicago Pritzker School of Medicine and received his Ph.D. in Biochemistry from the University of Chicago. He also trained at the National Institutes of Health in Pathology and Chemical Physics.Read More +Read Less -
Dr. O’Neill has an active basic and translational research program. His current research focuses on the pathophysiology of vascular calcification in renal failure specifically on the role of endogenous pyrophosphate in the etiology of vascular calcification. In addition, the role of other factors including vitamin D and matrix GLA protein is being investigated along with possible mechanisms for reversal of vascular calcification.
Dr. O’Neill received his M.D. from Tufts University School of Medicine. He then completed a residency in internal medicine at Albany Medical Center followed by subspecialty training in endocrinology, diabetes, and metabolism at Tufts Medical Center and in nephrology at Emory University School of Medicine. Dr. O’Neill is board certified in internal medicine, endocrinology diabetes and metabolism, and nephrology.Read More +Read Less -
Yves Sabbagh, Ph.D., is our senior vice president and chief scientific officer, joining Inozyme in October 2020. Dr. Sabbagh brings to Inozyme more than 20 years of experience in rare genetic disorders and mineral metabolism with responsibilities leading to the identification and evaluation of novel therapeutic approaches and translating them into clinical candidates.
Prior to joining Inozyme, Dr. Sabbagh served as the head of rare renal and musculoskeletal diseases research at Sanofi. Prior to that executive role, he held scientific roles of increasing responsibility at Sanofi and Genzyme Corporation spanning endocrine, renal and rare bone diseases including driving the strategy for bone indications. Prior to his corporate experience, he was an instructor at the Harvard Medical School in the Endocrine unit. Dr. Sabbagh has co-authored more than 30 peer-reviewed publications and book chapters and is a member of several scientific societies. Dr. Sabbagh received a B.Sc. in biochemistry from McGill University, an MSc in microbiology from Université Laval and a Ph.D. in biology from McGill University.Read More +Read Less -
Joseph Schlessinger has been the William H. Prusoff Professor and Chairman of the Department of Pharmacology at Yale University School of Medicine since 2001. He served as the Director of the Skirball Institute for Biomolecular Medicine at New York University (NYU) Medical Center and the Milton and Helen Kimmelman Professor and Chairman of the Department of Pharmacology at NYU Medical School.
He was a faculty member of the Weizmann Institute and the Ruth and Leonard Simon Professor of Cancer Research in the Department of Immunology. Dr. Schlessinger was a Research Director for Rorer Biotechnology. He founded Sugen, Inc. in 1991, Plexxikon in 2001, and Kolltan in 2008. Dr. Schlessinger holds a B.Sc. in chemistry and physics and an M.Sc. in chemistry from the Hebrew University in Jerusalem. He earned his Ph.D. in biophysics from the Weizmann Institute of Science in 1974. Dr. Schlessinger was a postdoctoral fellow in the Departments of Chemistry and Applied Physics at Cornell University, and he was a visiting fellow in the immunology branch of the National Cancer Institute of NIH.Read More +Read Less -
Edward Y. Skolnik is the former Norman S. Wikler Professor of Medicine and Director of the Division of Nephrology at the New York University Langone Medical Center. His current research interests focus on the regulation and function of the potassium channel KCa3.1 in lymphocyte and mast cell activation, and the role of histidine phosphorylation and dephosphorylation in regulating KCa3.1 and other biological processes.
The ultimate goal of these studies is to identify new targets to inhibit lymphocyte and mast cell activation and thereby treat autoimmune disease and allergy, as well as new targets to promote lymphocyte activation to enhance anti-tumor immunity. In addition, Dr. Skolnik’s lab studies autosomal dominant polycystic kidney disease, which is the most common hereditary cause of renal failure worldwide. Dr. Skolnik has received many awards for his research including election to the American Society of Clinical Investigation, American Association of Physicians, and the Interurban Clinical Club.Read More +Read Less -
Robert Terkeltaub is a Professor of Medicine at the University of California San Diego, where he joined the faculty in 1985 after completing his Immunopathology postdoctoral research training at the Scripps Research Institute in La Jolla, California.
His research achievements include works in translational inflammation and skeletal and arterial biology, clinical trials, management guidelines, and outcomes. With lab trainees and mentees, he published pioneering work in innate immunity-modulated and metabolically regulated chondrocyte pro-catabolic and pro-calcifying differentiation therapy targets for diseases of pathologic calcification and tissue degeneration. This includes seminal molecular identification of ENPP1 as the principal chondrocyte PPi-generating ectoenzyme. He identified autosomal recessive ENPP1 deficiency as molecular and genetic etiology of the severe arterial-periarticular calcifying orphan disease general arterial calcification of infancy (GACI). This work led to a broader recognition of GACI, genetic screening protocols, and now the development of biologic ENPP1 enzyme replacement therapy. He serves on multiple editorial boards and NIH and foundation scientific advisory committees. Dr. Terkeltaub is a graduate of McGill University, where he completed his medicine residency and Rheumatology Fellowship.Read More +Read Less -
David Thompson rejoined our leadership team in July 2021 as chief development officer, after previously serving as our senior vice president and chief scientific officer from 2018 to 2020. In his former role, Dr. Thompson was responsible for scientific research as the company built its proprietary pipeline of investigational therapies, beginning with INZ-701.
He has more than 30 years of experience designing and leading research and development programs focused on bone disorders and phosphate regulation. Prior to joining Inozyme Pharma, Dr. Thompson was a founder and president of Azure Biotech, where he was responsible for the development of a novel formulation of lasofoxifene, a non-steroidal selective estrogen receptor modulator used for the prevention and treatment of osteoporosis and the treatment of vaginal atrophy. Previously, Dr. Thompson held executive positions in clinical research and drug development in multiple biopharma companies, including Alexion Pharmaceuticals, where he led the clinical development of asfotase alfa for the treatment of hypophosphatasia; and Pfizer, where he oversaw the osteoporosis research and frailty discovery groups. While at Merck Research Labs, he conducted preclinical work and participated in the early clinical development of alendronate for the treatment of osteoporosis. Dr. Thompson received his M.A. from the University of Montana and both his M.S. and Ph.D. from the University of Connecticut.Read More +Read Less -
Paul B. Yu is a Physician-Scientist and Section Head of Cardiovascular Life Sciences at Brigham and Women’s Hospital and an Associate Professor of Medicine at Harvard Medical School.
Dr. Yu’s clinical interests include general cardiology, pulmonary vascular disease and cardiovascular disease associated with rheumatologic disease. His research focuses on how bone morphogenetic protein (BMP) and TGF-β signaling contribute to cardiopulmonary, systemic vascular, and musculoskeletal development, and how these signals may regulate physiology and tissue remodeling. Dr. Yu has contributed to more than 80 peer-reviewed publications. He received his M.D. from Duke University School of Medicine. He then completed a residency program in internal medicine at the University of California, San Francisco Medical Center, and a fellowship program in cardiovascular medicine at Massachusetts General Hospital. Dr. Yu is board certified in internal medicine and cardiovascular disease.Read More +Read Less -